Mazor Robotics Ltd – (NASDAQ:MZOR)’s share price shot up 4.9% during mid-day trading on Thursday . The stock traded as high as $23.64 and last traded at $23.45, with a volume of 139,806 shares trading hands. The stock had previously closed at $22.35.

Several research firms have issued reports on MZOR. Needham & Company LLC restated a “hold” rating on shares of Mazor Robotics Ltd – in a research note on Thursday, July 7th. Wells Fargo & Co. raised shares of Mazor Robotics Ltd – from a “market perform” rating to an “outperform” rating in a research report on Thursday, May 19th. Zacks Investment Research raised shares of Mazor Robotics Ltd – from a “sell” rating to a “hold” rating in a research report on Tuesday, June 14th. Sterne Agee CRT lowered shares of Mazor Robotics Ltd – from a “buy” rating to a “neutral” rating in a research report on Tuesday, May 31st. Finally, Barclays PLC upped their price target on shares of Mazor Robotics Ltd – from $16.00 to $23.00 and gave the company an “overweight” rating in a research report on Thursday, July 14th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $25.00.

The company’s 50 day moving average is $21.37 and its 200-day moving average is $14.67. The firm’s market capitalization is $500.65 million.

Mazor Robotics Ltd – (NASDAQ:MZOR) last posted its earnings results on Tuesday, August 2nd. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.02. The company earned $8.30 million during the quarter, compared to analysts’ expectations of $8.51 million. During the same quarter last year, the firm earned ($0.05) EPS. Mazor Robotics Ltd -‘s revenue for the quarter was up 6.4% on a year-over-year basis. On average, equities research analysts expect that Mazor Robotics Ltd – will post ($0.63) earnings per share for the current fiscal year.

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.